Impact of denosumab on bone high-resolution peripheral quantitative computed tomography (HRpQCT) in hemodialysis patients: a retrospective longitudinal observational study
Abstract
Background and hypothesis Denosumab increases bone mineral density (BMD) in dialysis patients, but the effects on bone microarchitecture using high-resolution peripheral quantitative computed tomography (HRpQCT) and the response factors to treatment are unknown. Methods We analyzed, at a single center between 2014 and 2024, 19 consecutive patients on hemodialysis having a longitudinal HRpQCT monitoring at the distal tibia and radius. After excluding the presence of osteomalacia based on bone biopsies and ensuring well-controlled parathyroid hormone levels, nine patients with recent fractures were treated with denosumab. Changes in HRpQCT parameters observed over time were analyzed within the denosumab group and were compared to a group of a nontreated patients, using linear mixed models for repeated measures. Baseline histomorphometric parameters were analyzed as predictors of changes in HRpQCT parameters over time in denosumab-treated patients. Results During a median [maximum–minimum] follow-up period of 2.1 [1.0–3.5] years, the nine denosumab-treated patients had a significant improvement of (i) bone volume-to-total volume ratio at the distal radius (+1.63% [95% confidence interval: 1.11–3.31] per year, P = .037) and tibia (+1.13% [0.10–2.28], P = .049), (ii) trabecular volumetric BMD at the distal radius (+1.58 [1.07–3.30], P = .039) and tibia (+0.95% [0.11–1.97], P = .039), (iii) trabecular number at the distal radius (+1.86% [0.45–3.28], P = .017), and (iv) trabecular separation at the distal radius (−1.83% [−3.16 to −0.50], P = .014). These changes were also significant when compared with those of the untreated group. Changes in cortical parameters did not change significantly over time. At most, changes in trabecular volumetric BMD at the radius were negatively associated with osteoid volume. Conclusion Denosumab improves HRpQCT trabecular bone parameters without significant effect on cortical parameters in dialysis patients.
Related
- Changes in Nutritional Status and Bioimpedance Parameters During EAA/KA Supplementation in Elderly Patients Undergoing Maintenance Hemodialysis: A Retrospective Observational Study
- Clinical Disease Activity and Power Doppler Changes Observed During a Multimodal Rehabilitation Program in Rheumatoid Arthritis: A Retrospective Longitudinal Observational Study
- Plasma Osteoprotegerin and Cardiovascular Mortality During the First Two Years of Maintenance Hemodialysis: A Prospective Observational Cohort Study.
- Association of Ultrafiltration Rate with Structural Remodeling of the Left Heart and Arrhythmias in Hemodialysis Patients: A Cross-Sectional Observational Study.
- Predictors of physical performance decline in patients receiving maintenance hemodialysis: a prospective observational study
BibTeX
@article{batteux2026impact,
title = {{Impact of denosumab on bone high-resolution peripheral quantitative computed tomography (HRpQCT) in hemodialysis patients: a retrospective longitudinal observational study}},
author = {Benjamin Batteux and Ana Pimentel and Agnes Ostertag and Tilman Drüeke and Martine Cohen-Solal and Pablo Antonio Urena Torres},
journal = {Clinical Kidney Journal},
year = {2026},
month = sep,
doi = {10.1093/ckj/sfag182},
url = {https://u-picardie.hal.science/hal-05762103v1},
note = {CC BY},
}
RIS
TY - JOUR
TI - Impact of denosumab on bone high-resolution peripheral quantitative computed tomography (HRpQCT) in hemodialysis patients: a retrospective longitudinal observational study
AU - Benjamin Batteux
AU - Ana Pimentel
AU - Agnes Ostertag
AU - Tilman Drüeke
AU - Martine Cohen-Solal
AU - Pablo Antonio Urena Torres
PY - 2026
DA - 2026/09/21
JO - Clinical Kidney Journal
DO - 10.1093/ckj/sfag182
UR - https://u-picardie.hal.science/hal-05762103v1
AB - Background and hypothesis Denosumab increases bone mineral density (BMD) in dialysis patients, but the effects on bone microarchitecture using high-resolution peripheral quantitative computed tomography (HRpQCT) and the response factors to treatment are unknown. Methods We analyzed, at a single center between 2014 and 2024, 19 consecutive patients on hemodialysis having a longitudinal HRpQCT monitoring at the distal tibia and radius. After excluding the presence of osteomalacia based on bone biopsies and ensuring well-controlled parathyroid hormone levels, nine patients with recent fractures were treated with denosumab. Changes in HRpQCT parameters observed over time were analyzed within the denosumab group and were compared to a group of a nontreated patients, using linear mixed models for repeated measures. Baseline histomorphometric parameters were analyzed as predictors of changes in HRpQCT parameters over time in denosumab-treated patients. Results During a median [maximum–minimum] follow-up period of 2.1 [1.0–3.5] years, the nine denosumab-treated patients had a significant improvement of (i) bone volume-to-total volume ratio at the distal radius (+1.63% [95% confidence interval: 1.11–3.31] per year, P = .037) and tibia (+1.13% [0.10–2.28], P = .049), (ii) trabecular volumetric BMD at the distal radius (+1.58 [1.07–3.30], P = .039) and tibia (+0.95% [0.11–1.97], P = .039), (iii) trabecular number at the distal radius (+1.86% [0.45–3.28], P = .017), and (iv) trabecular separation at the distal radius (−1.83% [−3.16 to −0.50], P = .014). These changes were also significant when compared with those of the untreated group. Changes in cortical parameters did not change significantly over time. At most, changes in trabecular volumetric BMD at the radius were negatively associated with osteoid volume. Conclusion Denosumab improves HRpQCT trabecular bone parameters without significant effect on cortical parameters in dialysis patients.
SN - 2048-8505
SN - 2048-8513
ER -